Everything below concerns receptor agonist. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-11-13. Numbers and descriptions here follow the published literature rather than marketing material.
Identity and purity are usually assessed by reverse-phase high-performance liquid chromatography coupled to mass spectrometry. Retention time and observed mass are compared against a reference standard run under identical conditions. Impurity profiles reveal deamidation products, oxidized methionine variants, and truncated fragments that arise during synthesis or storage. Peptide mapping through enzymatic digestion confirms the primary sequence, while amino acid analysis offers an independent check on overall composition.
Stability studies examine how temperature, pH, and moisture influence degradation rates over time. In aqueous solution, hydrolysis and deamidation accelerate as pH moves away from mildly acidic conditions. Light exposure and residual metal ions can also trigger oxidation of susceptible residues. Accelerated aging at elevated temperature is used to estimate shelf life, though extrapolation to room temperature carries uncertainty because individual degradation pathways do not always scale predictably.
Quality control for peptide material focuses on identity, purity, content and the profile of impurities. Common degradants include deamidated and oxidised forms, plus aggregates formed during storage or handling. Forced degradation studies under heat, light, acid and peroxide help define which conditions accelerate change and which analytical methods detect it. Limits for individual impurities are set by pharmacopoeial monographs or manufacturer specifications. How much a given impurity affects biological activity is often uncertain, and conclusions may depend on the assay used.
Solid peptide material is generally kept at reduced temperature to limit degradation. Short-term storage at 2 to 8 degrees Celsius is common, while longer archival storage at minus 20 degrees Celsius or below is typical for lyophilised powder. Vials should remain sealed and protected from light, because ultraviolet exposure can oxidise susceptible residues. Repeated freeze-thaw cycles are avoided, as they promote aggregation and loss of soluble material. Solutions are less stable than solids and are usually prepared close to the time of use.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Batch-to-batch variation is normal |
| Solubility class | Soluble in water, buffer, and dimethyl sulfoxide | Aqueous solubility is moderate |
| Typical storage temperature | Minus 20 degrees Celsius dry, 2 to 8 degrees Celsius reconstituted | Avoid repeated freeze-thaw |
| Common analytical method | Reverse-phase HPLC with electrospray mass detection | Used for purity and mass confirmation |
| Common synonyms | GLP-1 analog, semaglutide peptide | Wording varies across suppliers |
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
Development began in the early 2010s with the goal of extending GLP-1 activity beyond the brief window achieved by native peptide infusion. The earliest approved formulation was a subcutaneous injection given once weekly. A later oral tablet pairs the peptide with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, usually shortened to SNAC. That carrier lowers local pH and helps the peptide cross gastric tissue. Both routes deliver the same active molecule.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, a gut hormone released after meals. Its backbone retains the GLP-1 sequence but incorporates two substitutions that slow enzymatic breakdown by dipeptidyl peptidase-4. A short polyethylene glycol linker and a C18 fatty diacid are attached to the peptide chain, allowing the molecule to bind serum albumin and remain in circulation far longer than the native hormone. The result is a circulating half-life measured in days rather than the minutes typical of endogenous GLP-1.
Receptor activation occurs at GLP-1 receptors distributed across pancreatic islets, the hypothalamus, and the gastrointestinal tract. Binding triggers G protein signaling that raises cyclic AMP and enhances glucose-dependent insulin release. Because the effect depends on prevailing glucose levels, insulin secretion does not rise when blood sugar is already low. Signaling in the brain and gut also influences appetite and gastric emptying, which is why the compound appears in both metabolic and weight-related research literature.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
Pale stools occur when stercobilin, a brown pigment, is absent from the stool. Stercobilin is derived from bilirubin metabolites produced in the liver. Dark urine occurs when bilirubin mixes with urine
interstitial compound A compound composed of a transition metal bonded to either hydrogen, boron, carbon, or nitrogen, whose crystal structure consists of closely packed metal ions with the non-metal atoms located in the interstices.
=== Newborn === Newborns of mammals are exceptional in protein digestion and assimilation in that they can absorb intact proteins at the small intestine. This enables passive immunity, i.e., transfer of immunoglobulins from the mother to the newborn, via milk.
A study by Aphekom comparing ten large French cities showed that Le Havre is the least polluted urban commune of France. Le Havre is also the third best city in France with more than 100,000 inhabitants for air quality. A Carbon accounting showed in 2009 that the municipality ejected some 32,500 tonnes of CO2 per year. In 2011 the average annual emissions of sulfur dioxide by industry was between three micrograms per cubic metre in the centre of Le Havre to twelve micrograms per cubic metre in the district of Caucriauville. The municipality has set a target to reduce emissions of CO2 by 3% per year. To achieve this solar panels have been installed on several municipal buildings (city hall, hanging gardens). Since 2008, Le Havre has been part of the network of Energy Cities and, in this context, it applies the steps of Agenda 21 and an Environmental Approach to Urban Planning. The city has received many awards of eco-labels several times (Energy of the Future label in 2009–2011, sustainable Earth label in 2009). Since 1998, Le Havre's beach has received the Blue Flag yearly thanks to its range of facilities, which extend over 30,000 m2. Le Havre has kept extensive green areas (750 hectares or 41 m2 per inhabitant), the two largest areas are the Montgeon Forest and Rouelles Park which are both located in the upper town. The gardens of the Priory of Graville and the hanging gardens offer views of the lower city. In the city centre, Saint-Roch Square and the City Hall Gardens provide the people with urban recreation areas.
=== Basal regulation === Under normal, unstressed conditions, p53 is maintained at low levels through continuous degradation mediated by the E3 ubiquitin ligase MDM2 (HDM2 in humans). MDM2 binds p53, exports it from the nucleus, and targets it for proteasomal degradation. Notably, p53 transcriptionally activates MDM2, establishing a classic negative feedback loop. This feedback loop gives rise to damped oscillations in p53 levels, as demonstrated both experimentally and in mathematical models. These oscillations may determine cell fate decisions between survival and apoptosis.
Sources: en.wikipedia.org
=== Absorption and distribution === As calciseptine is injected by the snake into its prey along with the rest of its venom, it does not have to pass the protective barrier of the skin and is injected directly into the tissues and/or bloodstream of the prey. No research has been conducted on the toxicokinetics of calciseptine specifically, but general research about snake toxin dynamics is available. Although the toxic peptides are generally small (about 60 amino acids), their size is sufficient to prevent them from crossing epithelial layers like the blood–brain barrier. Bioavailability measurements have been conducted for several snake venoms. For example, cobra venom has been found to have a bioavailability of 41.7% when injected intramuscular, and for other venoms this may even be less than 10%. These values are quite low compared to those of most therapeutic drugs, which usually have a bioavailability of nearly 100% after intramuscular injection. In general, toxic peptides of 10-40 amino acids have been found to have a relatively poor bioavailability due to their size and hydrophilicity. Thus, calciseptine, containing 60 amino acids, is expected to have a low bioavailability as well.
== Ribose 5-phosphates: histidine == In E. coli, the biosynthesis begins with phosphorylation of 5-phosphoribosyl-pyrophosphate (PRPP), catalyzed by ATP-phosphoribosyl transferase. Phosphoribosyl-ATP converts to phosphoribosyl-AMP (PRAMP). His4 then catalyzes the formation of phosphoribosylformiminoAICAR-phosphate, which is then converted to phosphoribulosylformimino-AICAR-P by the His6 gene product. His7 splits phosphoribulosylformimino-AICAR-P to form D-erythro-imidazole-glycerol-phosphate. After, His3 forms imidazole acetol-phosphate releasing water. His5 then makes L-histidinol-phosphate, which is then hydrolyzed by His2 making histidinol. His4 catalyzes the oxidation of L-histidinol to form L-histidinal, an amino aldehyde. In the last step, L-histidinal is converted to L-histidine.
Here, a stock solution of glutamine is added in increasing increments with a high-accuracy instrument and diluted to the same volume in volumetric flasks. The result is 4 standard solutions with varying known concentrations (along with a blank for instrument calibration). The final concentration in each is calculated using the formula for molar concentration.
Canada is a federation composed of 10 federated states, called provinces, and three federal territories. These may be grouped into four main regions: Western Canada, Central Canada, Atlantic Canada, and Northern Canada (Eastern Canada refers to Central Canada and Atlantic Canada together). Provinces and territories have responsibility for social programs such as healthcare, education, and social programs, as well as administration of justice (but not criminal law). Although the provinces collect more revenue than the federal government, equalization payments are made by the federal government to ensure reasonably uniform standards of services and taxation are kept between the richer and poorer provinces. The major difference between a Canadian province and a territory is that provinces receive their sovereignty from the Crown and power and authority from the Constitution Act, 1867, whereas territorial governments have powers delegated to them by the Parliament of Canada and the commissioners represent the King in his federal Council, rather than the monarch directly. The powers flowing from the Constitution Act, 1867, are divided between the federal government and the provincial governments to exercise exclusively and any changes to that arrangement require a constitutional amendment, while changes to the roles and powers of the territories may be performed unilaterally by the Parliament of Canada.
Barbiturates Benzodiazepines Ethanol (drinking alcohol; ethyl alcohol) Nonbenzodiazepines Others carisoprodol (Soma) chloral hydrate diethyl ether ethchlorvynol (Placidyl; "jelly-bellies") gamma-butyrolactone (GBL, a prodrug to GHB) gamma-hydroxybutyrate (GHB; G; Xyrem; "Liquid Ecstasy", "Fantasy") glutethimide (Doriden) kava (from Piper methysticum; contains kavalactones) ketamine, a phencyclidine (PCP) analog meprobamate (Miltown) methaqualone (Sopor, Mandrax; "Quaaludes") phenibut propofol (Diprivan), a general anesthetic theanine (found in Camellia sinensis, the tea plant) valerian (from Valeriana officinalis)
Sources: en.wikipedia.org
=== Styrene-butane co-polymers === Styrene-butane co-polymers can be produced with a low butene content. Styrene-butane co-polymers include PS-I and SBC (see below), both co-polymers are impact resistant. PS-I is prepared by graft co-polymerization, SBC by anionic block co-polymerization, which makes it transparent in case of appropriate block size. If styrene-butane co-polymer has a high butylene content, styrene-butadiene rubber (SBR) is formed. The impact strength of styrene-butadiene co-polymers is based on phase separation, polystyrene and poly-butane are not soluble in each other (see Flory–Huggins solution theory). Co-polymerization creates a boundary layer without complete mixing. The butadiene fractions (the "rubber phase") assemble to form particles embedded in a polystyrene matrix. A decisive factor for the improved impact strength of styrene-butadiene copolymers is their higher absorption capacity for deformation work. Without applied force, the rubber phase initially behaves like a filler. Under tensile stress, crazes (microcracks) are formed, which spread to the rubber particles. The energy of the propagating crack is then transferred to the rubber particles along its path. A large number of cracks give the originally rigid material a laminated structure. The formation of each lamella contributes to the consumption of energy and thus to an increase in elongation at break. Polystyrene homo-polymers deform when a force is applied until they break.
== Adverse effects == Its most common adverse effects are transient nausea and vomiting, dizziness, drowsiness, fatigue, headache, and nervousness; less commonly, nausea and vomiting (after repeated dosing), hallucinations, confusion, euphoria, tremor, hyperreflexia, clonus, and increased sweating. Uncommonly, somnolence; rarely, diarrhoea and abdominal pain.
=== Topical application === Topically applied sodium hyaluronate can facilitate the absorption of biomacromolecules, i.e. pharmaceuticals, and function like a nanocarrier. Its effects on skin depend on the hyaluronate formulation and skin health: In barrier-deficient skin it restricted the delivery of biomacromolecules to the stratum corneum and viable epidermis. In normal skin, low-molecular weight hyaluronate (5 kDa) enhanced penetration into the epidermis. Transepidermal water loss increased by 55.5% with low-molecular weight, and was reduced by 28% with crosslinked resilient, and by 16% with HMW. Its efficacy against wrinkles has not been tested in clinical trials. Dry, scaly skin, such as that caused by atopic dermatitis, may be treated with lotion or another skin product containing sodium hyaluronate as its active ingredient. After instillation into the lung, higher molecular weight hyaluronate appears to persist longer in the lung but if > 215 kD there was poor lung penetration and mucociliary clearance. Hyaluronate could allow access to lymph nodes draining the pulmonary bed.
2000 – 2008 Member of the board of the Technical University of Denmark. 2000 – 2003 Member of the Academy of Technical Sciences, Denmark 2003 – 2004 President of the Academy of Technical Sciences, Denmark 2006 – 2012 Member of the board of Cellartis AB, Sweden 2012 – 2019 Member of the board of the University of Copenhagen (chairman from 2017 to 2020) 2014 - 2016 Chairman of the board, Steno Diabetes Center, Denmark 2018 - 2019 Board member, Symphogen A/S, Denmark 2020 - Member of the board of BB Biotech AG, Switzerland
China was identified as interfering with the 2024 election through propaganda and disinformation campaigns linked to its Spamouflage operation. U.S. intelligence agencies described the effort as not targeting any particular candidate but focusing on issues important to the Chinese government, such as Taiwan, and "undermining confidence in elections, voting, and the U.S. in general". As early as April 1, 2024, The New York Times reported that the Chinese government had created fake pro-Trump accounts on social media "promoting conspiracy theories, stoking domestic divisions and attacking President Biden ahead of the election in November".
Sources: en.wikipedia.org
Manufacturers commonly state multi-year stability when the powder is kept dry and frozen. Actual shelf life depends on residual moisture, vial sealing, and storage temperature. A re-test by chromatography is the only way to confirm remaining purity.
Deamidated and oxidized forms are the most frequently reported impurities. Truncated peptide fragments from incomplete synthesis also appear at low levels. Their relative abundance grows with time, heat exposure, and unfavorable pH.
Retention time matching on a validated column provides strong circumstantial evidence. It does not distinguish compounds with similar hydrophobicity. Mass measurement or peptide mapping is needed for unambiguous identification.
Lower temperatures slow hydrolysis, oxidation and aggregation reactions that degrade the molecule over time. Lyophilised powder is more tolerant than solution, but both benefit from controlled conditions.